Welcome to our dedicated page for Parkervision SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for ParkerVision, Inc. (PRKR), a Florida corporation focused on radio-frequency (RF) technologies for advanced wireless communication systems. Through its periodic and current reports, ParkerVision provides detailed information on its operations, financial condition, litigation posture, and capital-raising activities.
Investors can use ParkerVision’s annual reports on Form 10-K and quarterly reports on Form 10-Q to review its RF technology and licensing focus, operating expenses, net losses, contingent payment obligations, and cash flows. These filings also include risk factor discussions that the company references in its press releases, covering topics such as outcomes of patent litigation, interpretations of patent law and claim scope, decisions by the Patent Trial and Appeal Board (PTAB), and market conditions affecting financing.
Current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe registered direct offerings of common stock under ParkerVision’s effective shelf registration statement on Form S-3, including sales to accredited investors and to a director. These filings outline subscription agreements, offering prices, aggregate purchase amounts, and legal opinions regarding the issuance of securities. Other 8-Ks furnish earnings press releases that summarize quarterly and year-to-date financial results and provide context for changes in operating expenses and contingent payment obligations.
Through this filings page, users can access ParkerVision’s real-time updates as they are filed with EDGAR, including 10-K, 10-Q, and 8-K reports, as well as registration statements and prospectus supplements related to its shelf registration. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections such as litigation disclosures, capital structure changes, and risk factors, and make it easier to interpret complex legal and financial language without replacing the full primary documents.
ParkerVision reported an insider equity award to its leader. On January 22, 2026, Chief Executive Officer and director Jeffrey Parker received a grant of a performance-based nonqualified stock option covering 8,000,000 shares of ParkerVision common stock with an exercise price of $0.24 per share. The option vests based on specified performance conditions that are measured quarterly over a five-year performance period. Any portion of the option that has not vested by January 22, 2031 will be cancelled. After this grant, Parker is shown as directly holding 8,000,000 derivative securities related to this option.
ParkerVision Inc. Chief Financial Officer Cynthia L. French reported the grant of two nonqualified stock option awards. On January 22, 2026, she was awarded 500,000 nonqualified stock options with an exercise price of
ParkerVision Inc. director Paul A. Rosenbaum received a stock option grant as part of his 2026 Board compensation. On January 22, 2026, he was awarded an option to purchase 370,000 shares of ParkerVision common stock at $0.24 per share, held directly. This option represents his beneficial ownership of 370,000 derivative securities after the transaction.
The option vests in two equal installments, with half vesting on July 22, 2026 and the remaining half on January 22, 2027, aligning the award with continued Board service over that period.
ParkerVision Inc. director Lewis H. Titterton Jr. reported an award of stock options as compensation for 2026 Board service. On January 22, 2026, he received an option to purchase 370,000 shares of common stock at an exercise price of $0.24 per share. Following this grant, he beneficially owns 370,000 derivative securities directly. The option vests in two equal installments on July 22, 2026 and January 22, 2027, aligning vesting with his Board service period.
ParkerVision Inc. reported a stock option award to director Robert Greene Sterne. On January 22, 2026, he received an option to purchase 370,000 shares of common stock at an exercise price of $0.24 per share, expiring January 22, 2031.
The option is compensation for 2026 Board service and vests in two equal installments on July 22, 2026 and January 22, 2027. After this grant, Sterne beneficially owns 370,000 derivative securities directly.
ParkerVision, Inc. filed a prospectus supplement tied to an existing resale registration covering up to 9,387,500 shares of common stock. These shares include stock already issued under prior securities purchase agreements, shares issuable upon conversion of certain convertible notes at a fixed price of $0.16 per share, and shares issuable upon exercise of options granted as payment for services. The company will not receive proceeds from resales by the selling shareholders, but could receive up to $42,620 in gross proceeds if the service options are exercised for cash.
Separately, the compensation committee granted performance-based stock options for up to 8,000,000 shares to the CEO and 500,000 shares to the CFO, plus a time-based option for 500,000 shares to the CFO, all with a $0.24 exercise price. The performance options vest based on cumulative net cash from patent enforcement actions and can accelerate if the company’s market capitalization reaches $1 billion for twenty consecutive trading days or upon a change in control. The committee also approved a 2.5% cost-of-living increase to the CEO’s and CFO’s base salaries.
ParkerVision, Inc. filed a prospectus supplement that updates its existing resale registration covering up to 16,638,353 shares of common stock issuable upon conversion of, and as interest paid in stock on, convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share.
The supplement incorporates a recent report describing new equity incentives for executives. The compensation committee granted performance-based stock options to the CEO for up to 8,000,000 shares and to the CFO for up to 500,000 shares, plus a time-based option for the CFO for up to 500,000 shares, all with a $0.24 exercise price. Vesting for the performance awards is tied to cumulative net cash from patent enforcement actions, with accelerated vesting if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CEO and CFO also received a 2.5% cost-of-living salary increase effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement covering the resale by a selling stockholder of up to 1,578,946 shares of common stock, including 1,052,631 existing shares and 526,315 shares issuable upon exercise of warrants. The company will not receive proceeds from resales, but could receive up to
The attached report also describes new equity awards for executives under the 2019 Long-Term Incentive Plan. The CEO received a performance-based option for up to 8,000,000 shares and the CFO received a performance-based option for up to 500,000 shares, both with a
ParkerVision, Inc. has a prospectus supplement covering the resale by existing stockholders of up to 13,342,953 shares of common stock, including shares previously issued in securities purchase agreements, shares underlying warrants, and shares issued as payment for services. The company will not receive any proceeds from stockholder resales, but could receive up to
The filing also describes new equity incentives for executives. The CEO received a performance-based stock option for up to 8,000,000 shares and the CFO received a performance-based option for up to 500,000 shares, both with a
ParkerVision, Inc. filed a prospectus supplement covering the resale by existing holders of up to 5,871,584 shares of common stock; the company will not receive any proceeds from these sales. The supplement incorporates a new current report detailing significant equity incentives for senior management.
The compensation committee granted the CEO a performance-based stock option for up to 8,000,000 shares and the CFO a performance-based option for up to 500,000 shares, each with a five-year performance period, ten-year term, and an exercise price of $0.24 per share. Vesting depends on cumulative net cash received from patent enforcement actions and can accelerate if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares vesting over two years, and both executives will receive a 2.5% cost-of-living salary increase effective April 15, 2026.